Video Experimental Relacionado

Updated: Sep 8, 2025

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

Identificación de una nueva estructura de núcleo de inhibidores de Apo-Ido1 a través de cribado virtual y

Yekui Yin^1,2,3, Meiqi He^1,2,3, Jianda Yue^1,2,3

¹The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha 410081 Hunan, China.

Journal of chemical information and modeling

|September 5, 2025

Resumen

Los investigadores desarrollaron un flujo de trabajo de detección virtual para descubrir nuevos inhibidores de la indoleamina 2,3-dioxigenasa 1 (IDO1). Este enfoque identificó potentes inhibidores de apo-IDO1, ofreciendo una estrategia prometedora para el desarrollo de fármacos contra el cáncer.

Área de la Ciencia:

Bioquímica y Biología Molecular
Química computacional
Farmacología

Sus antecedentes:

La indoleamina 2,3-dioxigenasa 1 (IDO1) es un objetivo terapéutico validado para el cáncer y las enfermedades neurodegenerativas.
Los inhibidores tradicionales de IDO1 se enfrentan a desafíos debido a su limitada eficacia clínica.
Los inhibidores de Apo-IDO1 presentan una nueva estrategia para la inhibición selectiva y duradera de IDO1.

Objetivo del estudio:

Establecer un flujo de trabajo virtual (VS) para la identificación de nuevos inhibidores de la apo-IDO1.
Para descubrir y optimizar pequeñas moléculas dirigidas a apo-IDO1.
Proporcionar un punto de partida para el desarrollo de nuevas terapias contra el cáncer.

Principales métodos:

Flujo de trabajo de cribado virtual que incorpora el acoplamiento molecular y la metadinámica de la postura de unión (BPMD).
Evaluación biológica de los compuestos afectados identificados para la selectividad de apo-IDO1 y la interrupción de la unión al hemo.
Simulaciones de dinámica molecular (MD acelerado aleatorio, mapas de autoorganización) para la optimización de la estructura y la exploración del mecanismo.

Principales resultados:

Identificación de un compuesto afectado, MQ-1 (IC50 = 1,29 μM), con focalización selectiva en apo-IDO1 y disrupción de la unión al hemo.
La optimización de MQ-1 condujo a análogos con una actividad inhibidora significativamente mejorada, como MQ-1n (IC50 = 0,29 μM).
El flujo de trabajo VS demostró ser eficaz para IDO1 y aplicable a objetivos enzimáticos similares.

Conclusiones:

El flujo de trabajo de VS desarrollado es una herramienta poderosa para descubrir nuevos inhibidores de apo-IDO1.
La estructura del núcleo del inhibidor de apo-IDO1 identificado tiene potencial para el futuro desarrollo de fármacos contra el cáncer.
Este estudio valida la inhibición de apo-IDO1 como una estrategia terapéutica viable.

Más Videos Relacionados

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Videos de Conceptos Relacionados

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Induced-fit Model

Induced-fit Model

Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...